Characteristics and indications of topiramate;Características e indicaciones del topiramato

Revista de Neurologia

Volumn 35, Issue SUPPL. 1, 2002, Pages

  Nieto Barrera, Manuel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Essential tremor; Generalized epilepsy; Neuropathic pain; Partial epilepsy; Topiramate; West's syndrome

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARBONATE DEHYDRATASE INHIBITOR; CLOZAPINE; DICLOFENAMIDE; DIGOXIN; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PLACEBO; PRIMIDONE; TOPIRAMATE; VALPROIC ACID;

ABSENCE; ADOLESCENT; ADULT; ANHIDROSIS; ANOREXIA; ANTICONVULSANT THERAPY; ARTICLE; BIPOLAR DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSARTHRIA; EATING DISORDER; EPILEPSY; ESSENTIAL TREMOR; FOCAL EPILEPSY; HEADACHE; HUMAN; LENNOX GASTAUT SYNDROME; MAJOR CLINICAL STUDY; MENTAL DISEASE; MIGRAINE; MULTICENTER STUDY; MYOCLONUS EPILEPSY; NEPHROLITHIASIS; NEUROPATHIC PAIN; NEUROPROTECTION; NEUROTOXICITY; NYSTAGMUS; PARESTHESIA; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEIZURE; SOMNOLENCE; TONIC CLONIC SEIZURE; WEST SYNDROME;

ANIMALS; ANTICONVULSANTS; BIPOLAR DISORDER; CLINICAL TRIALS; DRUG INTERACTIONS; EATING DISORDERS; EPILEPSY; FRUCTOSE; HUMANS; MIGRAINE DISORDERS; MULTICENTER STUDIES; NEUROPROTECTIVE AGENTS; PAIN; SPAIN;

EID: 0036763717     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Shank RP, Gardocki JF, Vaught JL, Davis CB, Schupsky JJ, Raffa RB, et al. Topiramate: Preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994; 35: 450-60.
2. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of Topiramate: Pharmacology, pharmacokinetics and mechanism of action. Epilepsia 2000; 41 (Suppl 1): S3-9.
3. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 2000; 41 (Suppl 1): S17-20.
4. Nakamura J, Tamura S, Kanda T, Ishii A, Ishihara K, Serikawa T, et al. Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur J Pharmacol 1994; 254: 83-9.
5. Edmonds HL Jr, Jiang YD, Zhand PY, Shank RP. Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemiainduced epilepsy. Life Sci 1996; 59: PL127-31.
6. Wauquier A, Zhou S. Topiramate: A potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res 1996; 24: 73-7.
7. DeLorenzo RJ, Sombati S, Coulter DA. Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons. Epilepsia 2000; 41 (Suppl 1): S40-4.
8. McLean MJ, Bukhari AA, Wamil AW. Effects of topiramate on sodium-dependent potential firing by mouse spinal cord neurons in cell culture. Epilepsia 2000; 41 (Suppl 1): S21-4.
9. Blaise FD, Bourgeois MD. Pharmacokinetics and pharmacodynamics of topiramate. Original article. J Child Neurol 2000; 15 (Suppl 1): S27-30.
10. White HS, Brown SD, Woodhead JH, Skeen GA, Wolff HH. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increase seizure threshold. Epilepsy Res 1997; 27: 167-79.
11. Biggs JW, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: Bookcase of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000; 41 (Suppl 1): S10-6.
12. Skaradski S, Withe HS. Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia 2000; 41 (Suppl 1): S45-7.
13. Zhang X, Veluminan AA, Jones OT, Carlen PL. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 2000; 41 (Suppl 1): S52-60.
14. Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isozymes. Epilepsia 2000; 41 (Suppl 1): S35-9.
15. Perucca E. Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. Epilepsia 1996; 37 (Suppl 2): S8-13.
16. Easterling DE, Zakszewski T, Moyer MD, Margul BL, Marriot TB, Nayak RK. Plasma pharmacokinetics of topiramate, a new anticonvulsant, in humans. Epilepsia 1988; 29 (Suppl): S662.
17. Bourgeois BFD. Pharmacokinetic properties of current antiepileptic drugs. What improvements are needed? Neurology 2000; 55 (Suppl 1): S12-S17.
18. Rosenfeld WE, Doose DR, Walker SA, Baldassarre JS, Reife RA. A study of topiramate pharmacokinetics tolerability in children with epilepsy. Pediatr Neurol 1999; 20: 339-44.
19. Gisclon LG, Curtin CR, Kramer LD. The steady-state (SS) pharmacokinetics (PK) of phenytoin (Dilantin) and topiramate (Topamax) in epileptic patient on monotherapy, and during combination therapy. Epilepsia 1994; 35 (Suppl 8): 54.
20. Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR. Steady-state pharmacokinetics of topiramate an carbamazepine in patient with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996; 37: 774-80.
21. Doose DR, Walker SA, Pledger G, Lim P, Reife RA. Evaluation of phenobarbital and primidone/phenobarbital (primidone's active metabolite) plasma concentrations during multicenter, double-blind, placebo-controlled trials in outpatients with partial seizures. Epilepsia 1995; 36 (Suppl 3): S158.
22. Wilensky AJ, Ojamenn LM, Chmelis T, Margul BL, Doose DR. Topiramate pharmacokinetics in epileptic patients receiving carbamazepine. Epilepsia 1989; 30: 645.
23. Floren KL, Graves NM, Leppik IE, Remmel RP, Margul BL, Doose DR. Pharmacokinetics of topiramate in patients with partial epilepsy receiving phenytoin or valproate. Epilepsia 1989; 30: 646.
24. Rosenfeld WE, Liao S, Kramer LD, Schaefer PA. Comparison of steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and combination therapy. Epilepsia 1997; 38: 324-33.
25. Patsalos PN. The pharmacokinetic profile of topiramate. Rev Contemp Pharmacother 1999; 10: 155-62.
26. Liao S, Palmer M. Digoxin and topiramate drug interaction study in male volunteers. Pharm Res 1993; 10 (Suppl 10): S405.
27. Roselfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrome an ethynyl estradiol in patient with epilepsy. Epilepsia 1997; 38: 317-23.
28. Wilner A, Raymond K, Pollard R. Topiramate and metabolic acidosis. Epilepsia 1999; 40: 792-5.
29. Delanty N, French JA, Williams SF. Lamotrigine and topiramate combination therapy: Experience from post-marketing surveillance. Epilepsia 1998; 29 (Suppl 5): S662.
30. Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, Pledger G, and the Topiramate YP Study Group. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology 1999; 52: 1338-44.
31. Ritter F, Glauser TA, Elterman RD, Wyllie E, and the Topiramate YP Study Group. Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Epilepsia 2000; 41 (Suppl 1): S82-5.
32. Herranz JL. Topiramato: Antiepiléptico de amplio espectro, administrado a 224 pacientes con epilepsias rebeldes. Rev Neurol 2000; 31: 822-8.
33. Candau Fernández-Mensaque R, Nieto Jiménez M, Nieto Barrera M. Eficacia de Topiramato en Epilepsias Parciales. En Síndromes Epilépticos Catastróficos. Saunderton: Janssen-Cilag; 2001. p. 109-18.
34. Candau R, Lluch Fernández MD, Nieto-Barrera M, Sierra Rodríguez J, Cruz Guerrero G, et al. Topiramate as adjunctive therapy in patients with partial-onset seizures with automatisms. Epilepsia 2000; 41 (Suppl Florence): S61.
35. Gilliam FG, Reife R, Wu SC. Topiramate monotherapy: Randomized controlled trial in patients with recently diagnosed localizationrelated epilepsy. Neurology 1999; 52 (Suppl 2): A248.
36. Privitera MD, Brodie MJ, Neto W, Wang S, and the Topiramate EPMN- 105 Study Group. Monotherapy in newly diagnosed epilepsy: Topiramate vs investigator choice of carbamazepine or valproate. Abstract Annual Meeting of the AES. Los Angeles. December, 2000.
37. Candau Fernández-Mensaque R, Nieto Barrera M. Topiramato en Monoterapia en Epilepsias Infantiles. Etiología de las Epilepsias en el Niño. Saunderton: Janssen-Cilag; 2001. p. 161-8.
38. Ben-Menachem E, and the Topiramate YTC-E Study Group. A doubleblind trial of topiramate in patients with generalised tonic-clonic seizures of non-focal origin. Epilepsia 1997; 38 (Suppl 3): S60.
39. Biton V, Montouris GD, Ritter F, Riviello JJ, Reife R, Lim P, Pledger G, and the Topiramate YTC Study Group. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999; 52: 1330-7.
40. Montouris GD, Biton V, Rosenfeld WE, and the Topiramate YTC/ YTCE Study Group. Non-focal generalized tonic-clonic seizures: Response during long-term topiramate treatment. Epilepsia 2000; 41 (Suppl 1): S77-81.
41. Cross JH. Topiramate monotherapy for childhood absence seizures: Results from an open-label pilot study. Epilepsia 1999; 40 (Suppl 2): S164.
42. Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G, and the Topiramate YL Study Group. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 1999; 52: 1882-7.
43. Glauser TA, Levisohn PM, Ritter F, Sachdeo RC, and the Topiramate YL Study Group. Topiramate in Lennox-Gastaut syndrome: Open-label treatment patients completing a randomized controlled trial. Epilepsia 2000; 41 (Suppl 1): S86-90.
44. Guerreiro MM, Manreza ML, Scotoni AE, Vigonius U. A pilot study of topiramate in children with Lennox-Gastaut syndrome. Arq Neuropsiquiatr 1999; 57: 167-75.
45. Herranz JL, Arteaga R. Eficacia y tolerabilidad del topiramato a largo plazo en 44 niños con epilepsias rebeldes. Rev Neurol 1998; 28: 1049-53.
46. Glauser TA, Clarck PO, Strawsburg R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 1998; 39: 1324-8.
47. Glauser TA, Clarck PO, McGee K. Long-term response to topiramate in patients with West syndrome. Epilepsia 2000; 41 (Suppl 1): S91-4.
48. Nieto-Barrera M, Candau R, Nieto-Jiménez M, Correa A, Ruiz del Portal L. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure 2000; 9: 590-4.
49. Burkart P, Schneble H, Ziegler G. Topiramate in severe myoclonic convulsive epilepsy of infancy. Epilepsia 1999; 40 (Suppl 2): 179.
50. Symann S, Rucquoy M, Misson J. New hope for CSWS/ESES treatment. Topiramate? In Evarad P, Richelme C, Tardieu M, eds. 3rd EPNS Congress. Bologna: Monduzzi Editore SpA; 1999. p. 155-9.
51. Uldall P, Buchholt JM. Clinical experiences with topiramate in children with intractable epilepsy. Eur J Pediatr Neurol 1999; 3: 105-11.
52. Marcotte D. Use of topiramate, a new antiepileptic as a mood stabilizer. J Affect Disord 1998; 50: 245-51.
53. McElroy SL, Suppes T, Keck PE, Frye MA, Denicoff KD, Altshulo LL. Open-label adjunctive topiramate of bipolar disorders. Biol Psychiatry 2000; 15: 1025-33.
54. Chengappa KNR, Rathore D, Levine J, Atzert R, Solai L, Parepale H, et al. Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord 1999; 1: 42-53.
55. Viata E, Bilabert A, Rodríguez A, García-Castrillón A, Luna MJ, Arrufat E, et al. Efectividad y seguridad del topiramato en el trastorno bipolar resistente. Actas Esp Psiquiatr 2001; 29: 1-5.
56. Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: A clinical case series. J Clin Psychiatry 2000; 61: 368-72.
57. Abuzzahab FS, Brown VL. Anorexogenic effects of topiramate in Schizophrenia. Poster Annual Meeting American Psychiatric Association. New Orleans, May 2001.
58. Shuaib A, Ahmed F, Muratoglu M, Kochanski P. Topiramate in migraine prophylaxis: A pilot study. Cephalalgia 1999; 19: 379-80.
59. Edwards KR, Norton JA, O'Connor J. Efficacy of topiramate in migraine prevention. A retrospective chart analysis. Poster XVII World Congress of Neurol. London, June 2001.
60. Potter DL, Hart DE, Calder CS, Storey JR. A double-blind randomized, placebo-controlled study of topiramate in the prophylactic treatment of migraine with and without aura. Chephalalgia 2000; 20: 305.
61. Edwards KR, Glantz MJ, Norton JA, Cross N. Prophylactic treatment of episodic migraine with topiramate: A double-blind, placebo-controlled trial in 30 patients. Cephalalgia 2000; 30: 310.
62. Edwards KR, Glantz MJ, Button J, Norton JA, Whittaker T, Cross N. Efficacy and safety of topiramate in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study. Neurology 2000; 54 (Suppl 3): A81.
63. Gálvez R, Rodríguez López MJ, García Escolar M, de Andrés J, Ruiz Ortiz S, Aladaya C, et al. Topiramate: a novel approach to neuropathic pain syndromes [poster]. Worldwide Pain Conference. San Francisco, July 2000.
64. Haugh MJ, Connor GS. Favorable response of trigeminal neuralgia to the anticonvulsivant topiramate. A retrospective study [poster]. Worldwide Pain Conference. San Francisco, July 2000.
65. Connor GS. Topiramate as a novel treatment for essential tremor [poster]. Worldwide Pain Conference. San Francisco, July 2000.
66. Angehagen M, Hansson E, Ronnback L, Ben-Menachem E. Does topiramate (TPM) have protective effects on astroglia cells and neurons in primary cortical cultures. [abstract]. Epilepsia 1998; 39 (Suppl 6): S44.
67. 2+) changes in neurons and astroglial cells in primary culture [abstract]. Epilepsia 1999; 40 (Suppl 7): 16.
68. Yang Y, Shuaib A, Li Q, Siddiqui MM. Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization. Brain Res 1998; 804: 169-76.
69. Yang Y, Li Q, Shuaib A. Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate. Neuropharmacology 2000; 39: 881-8.
70. Koh S, Jensen FE. Topiramate blocks acute and chronic epileptogenesis in a rat model of perinatal hypoxic encephalopathy, abstract. Epilepsia 1999; 40 (Suppl 7): 5.
71. Niebauer M, Gruenthal M. Topiramate reduces neuronal injury after experimental status epilepticus. Brain Res 1999; 837: 263-9.
72. Janssen-Cilag. Topiramate and Psychosis. Data on File 6. Saunderton: Janssen-Cilag; 1998c.
73. Shorvon AD. Safety of topiramate: Adverse events and relationships to dosing. Epilepsia 1996; 37 (Suppl 2): S18-22.
74. Schdeo J. Topiramate clinical profile in epilepsy. Clin Pharmakinetic 1998; 34: 335-46.
75. Nieto-Jiménez M, Nieto-Barrera M, Candau R, Ruiz del Portal L. Trastorno de la termorregulación asociado al tratamiento con topiramato [abstract]. Rev Neurol 2000; (Supl): 93.
76. Schear MJ, Rowan AJ, Wiener JA, Haug SJ, Mindel JS. Druginduced myopia. Epilepsia 1990; 31: 643.
77. Datos facilitados por Janssen-Cilag.
78. Reife RA, Pledger G, Lim P, Karin M. Topiramate: Proved analysis of six placebo-controlled trials. Epilepsia 1996; 37 (Suppl 4): S74.
79. Kelly K, Stephen LG, Sills GJ, Brodie MJ. Topiramate in patients with learning disability and refractory epilepsy. Epilepsia 2002; 43: 399-402.